PharmaCyte Biotech, Inc. is a biotechnology company focused on developing cellular therapies for cancer using its proprietary cellulose based live cell encapsulation technology. The company’s lead product candidate CypCaps™ is intended for the treatment of locally advanced inoperable non metastatic pancreatic cancer. PharmaCyte Biotech, Inc. is incorporated in Nevada and maintains its headquarters in Las Vegas Nevada.
PharmaCyte Biotech, Inc. has not yet generated…
PharmaCyte Biotech, Inc. is a biotechnology company focused on developing cellular therapies for cancer using its proprietary cellulose based live cell encapsulation technology. The company’s lead product candidate CypCaps™ is intended for the treatment of locally advanced inoperable non metastatic pancreatic cancer. PharmaCyte Biotech, Inc. is incorporated in Nevada and maintains its headquarters in Las Vegas Nevada.
PharmaCyte Biotech, Inc. has not yet generated product revenue as it remains a development stage biotechnology firm. The company expects to receive income from licensing agreements royalty payments and future product sales related to its encapsulation technology and therapeutic candidates.
PharmaCyte Biotech, Inc. operates in the competitive field of cancer therapeutics where its cellulose based encapsulation technology offers advantages over alginate and other materials used by rivals. The technology provides durable capsules that resist rupture degradation and immune response while allowing long term storage of viable cells. The company has obtained orphan drug designation from the FDA and the European Medicines Agency for its pancreatic cancer therapy which grants potential market exclusivity. Competitors include numerous startups mid sized biotech firms large pharmaceutical companies and academic research centers pursuing various approaches to treat pancreatic cancer.
The company’s prospective customers are patients with locally advanced inoperable non metastatic pancreatic cancer hospitals oncology centers and healthcare providers that administer chemotherapy and cellular therapies. No specific customer names are disclosed in the filing.